Molnupiravir To Reach 105 LMICs Through MPP Agreement

Almost 30 Generics Manufacturers Will Be Producing Low-Cost Versions Of The Antiviral

Almost 30 generics firms based across 11 countries have signed up to agreements with the Medicines Patent Pool to facilitate the supply of oral COVID-19 treatment molnupiravir to 105 low- and-middle-income countries. The move follows an agreement signed in October by the MPP with Merck.

Molnupiravir capsules next to bottle
Molnupiravir will be supplied to 105 LMICs through the scheme • Source: Alamy

The Medicines Patent Pool has signed agreements with 27 generics manufacturers to supply oral COVID-19 medication molnupiravir to 105 low- and-middle-income countries (LMICs). The sublicense agreements are the result of the voluntary licensing agreement signed by the MPP and Merck Sharp & Dohme in October last year to facilitate affordable global access to molnupiravir.

Molnupiravir received emergency use authorization from the US Food and Drug Administration in December to treat mild-to-moderate COVID-19 in adults...

More from International

More from Geography

EUCOPE Wants Simpler Manufacturing Rules And Framework For Combined Trials Under EU Biotech Act

 

EU authorities must “take advantage” of the upcoming Biotech Act to reassess the bloc’s policies and “offset existing challenges” for small and midsized enterprises, trade association EUCOPE has said.

Trial Cancellations And Delays Persist For CROs Amid Biotech Slowdown

 
• By 

The whole contract research organization industry is being impacted by the current volatility in the pharmaceutical industry.

Citeline Japan Awards 2025 - Enter Now!

 

The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get your submissions in by this date. Sponsorship opportunities and tables for the event are also available.